Novel Therapeutic Agents in Waldenström’s Macroglobulinemia

Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström’s macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and hist...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Ghobrial, Irene M., Leleu, Xavier, Azab, Abdel Kareem, Runnels, Judith, Jia, Xiaoying, Ngo, Hai, Melhem, Molly, Azab, Feda, Sacco, Antonio, Quang, Phong, Burwick, Nicholas, Moreau, Anne-Sophie, Husu, Emanuel, Farag, Mena, Roccaro, Aldo
פורמט: Artigo
שפה:Inglês
יצא לאור: 2009
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3133646/
https://ncbi.nlm.nih.gov/pubmed/19362982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CLM.2009.n.022
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים